Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +46.70%
#2 Pons Pons +35.30%
#3 TENDIES TENDIES +30.77%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.97%
#5 Starpower Starpower +28.18%
#6 StonkBroker StonkBroker +24.66%
#7 SkyAI SkyAI +24.29%
#8 Mubarak Mubarak +21.63%
#9 Decred Decred +19.96%
#10 PondCoin PondCoin +19.72%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc.

PVCT
Kedudukan dalam Saham #28855
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm... Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy. This treatment is being explored for a range of adult solid tumor malignancies, encompassing melanoma and various gastrointestinal cancers (such as hepatocellular carcinoma, metastatic colorectal cancer to the liver, metastatic neuroendocrine tumors to the liver, and metastatic uveal melanoma to the liver). It also targets pediatric solid tumors, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Additionally, Provectus is advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) to combat a broad spectrum of conditions. These include adult solid tumors (such as head and neck, breast, testicular, and colorectal cancers), pediatric blood cancers like leukemia, acute respiratory syndromes such as coronavirus, infections caused by multi-drug resistant bacteria (specifically Gram-negative bacteria), and certain ocular conditions, notably infectious keratitis. Furthermore, the company is progressing PH-10, an investigational immuno-dermatology agent designed to address inflammatory skin conditions like psoriasis and atopic dermatitis. Originally established in 2002, the company was initially named Provectus Pharmaceuticals, Inc., before rebranding as Provectus Biopharmaceuticals, Inc. in December 2013. Its operations are headquartered in Knoxville, Tennessee.
Harga Saham
$0.0578
Modal Pasaran
$24.29M
Perubahan (1 hari)
1.40%
Perubahan (1 tahun)
-27.93%
Negara
US
Perdagangan Provectus Biopharmaceuticals, Inc. (PVCT)

Kategori

Healthcare
Nisbah P/B bagi Provectus Biopharmaceuticals, Inc. (PVCT)
Nisbah P/B pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Provectus Biopharmaceuticals, Inc., nisbah P/B semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/B syarikat ialah 0.
Sejarah nisbah P/B untuk Provectus Biopharmaceuticals, Inc. dari 2026 hingga 2026
Nisbah P/B pada akhir setiap tahun
Tahun Nisbah P/B Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/B untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/B Perbezaan Nisbah P/B Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH